Home › Compare › CHNXF vs EQR

CHNXF vs EQR: Dividend Comparison 2026

CHNXF yields 26490.07% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHNXF wins by $856500661636595056640.00M in total portfolio value
10 years
CHNXF
CHNXF
● Live price
26490.07%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$856500661636595056640.00M
Annual income
$850,187,174,759,804,400,000,000,000.00
Full CHNXF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — CHNXF vs EQR

📍 CHNXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHNXFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHNXF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CHNXF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHNXF
Annual income on $10K today (after 15% tax)
$2,251,655.63/yr
After 10yr DRIP, annual income (after tax)
$722,659,098,545,833,800,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, CHNXF beats the other by $722,659,098,545,833,800,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHNXF + EQR for your $10,000?

CHNXF: 50%EQR: 50%
100% EQR50/50100% CHNXF
Portfolio after 10yr
$428250330818297528320.00M
Annual income
$425,093,587,379,902,200,000,000,000.00/yr
Blended yield
99.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CHNXF
No analyst data
Altman Z
-135.2
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHNXF buys
0
EQR buys
0
No recent congressional trades found for CHNXF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHNXFEQR
Forward yield26490.07% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$856500661636595056640.00M ✓$40.5K
Annual income after 10y$850,187,174,759,804,400,000,000,000.00 ✓$3,819.61
Total dividends collected$856084953147245199360.00M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CHNXF vs EQR ($10,000, DRIP)

YearCHNXF PortfolioCHNXF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$2,659,707$2,649,006.62$11,248$547.57+$2.65M → CHNXF
2$661,311,349$658,465,463.27$12,701$666.53+$661.30M → CHNXF
3$153,718,184,329$153,010,581,185.41$14,405$814.59+$153718.17M → CHNXF
4$33,404,167,863,182$33,239,689,405,949.67$16,413$999.84+$33404167.85M → CHNXF
5$6,786,439,075,574,744$6,750,696,615,961,140.00$18,795$1,232.92+$6786439075.56M → CHNXF
6$1,289,019,706,709,597,000$1,281,758,216,898,732,000.00$21,639$1,527.95+$1289019706709.58M → CHNXF
7$228,909,915,433,776,940,000$227,530,664,347,597,670,000.00$25,057$1,903.80+$228909915433776.91M → CHNXF
8$38,007,474,205,860,660,000,000$37,762,540,596,346,516,000,000.00$29,197$2,385.87+$38007474205860656.00M → CHNXF
9$5,900,455,025,037,820,000,000,000$5,859,787,027,637,549,000,000,000.00$34,250$3,008.70+$5900455025037819904.00M → CHNXF
10$856,500,661,636,595,100,000,000,000$850,187,174,759,804,400,000,000,000.00$40,467$3,819.61+$856500661636595056640.00M → CHNXF

CHNXF vs EQR: Complete Analysis 2026

CHNXF — Stock

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.

Full CHNXF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CHNXF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHNXF vs SCHDCHNXF vs JEPICHNXF vs OCHNXF vs KOCHNXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.